* CorMedix Inc CRMD.OQ CRMD.O is expected to report
results on
May 15.
*
* Refinitiv's mean analyst estimate for CorMedix Inc is for
a
loss of 20 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for CorMedix
Inc is
$16, above its last closing price of $5.18.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2022 -0.19 -0.20 Missed -7
Sep. 30 2022 -0.22 -0.23 -0.17 Beat 25.5
Jun. 30 2022 -0.20 -0.21 -0.19 Beat 8.1
Mar. 31 2022 -0.22 -0.22 -0.18 Beat 18.2
Dec. -0.23 -0.20 Beat 14.3
31 2021
Sep. 30 2021 -0.17 -0.18 -0.22 Missed -24.5
Jun. 30 2021 -0.19 -0.17 -0.12 Beat 30.4
Mar. 31 2021 -0.18 -0.18 -0.20 Missed -8.7
This summary was machine generated May 13 at 02:01 GMT. All
figures in US dollars unless otherwise stated